Tempus announced that it has entered into an agreement to acquire Ambry Genetics, a leader in genetic testing. Under the terms of the agreement, Tempus will pay $375 million in cash and $225 million in shares at closing, of which $100 million will be subject to a lock-up agreement until one year post-transaction close. The deal is expected to be financed in part through a $300 million increase in short and long term debt provided by Ares, Tempus’ current lender. Ambry expects to generate greater than$300 million in revenue in calendar year 2024 and EBITDA of greater than$40 million. For more information on Ambry and its impact, see Tempus’ latest investor deck.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Cathie Wood’s ARK Investment bought 170.6K shares of Tempus AI today
- Largest borrow rate increases among liquid names
- Avacta,Tempus AI enter collaboration for AI-driven drug development
- Cathie Wood’s ARK Investment bought 103K shares of Tempus AI today
- Tempus AI price target raised to $57 from $48 at Loop Capital